Business Context and Reporting Period
This Form 8-K was filed by AIT Therapeutics, Inc. (not Beyond Air, Inc.) on January 29, 2019, reporting an event that occurred on January 23, 2019. The Company is an emerging growth company incorporated in Delaware. The filing details the entry into a Material Definitive Agreement with Circassia Limited.
Key Financial Metrics and Agreement Terms
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt) for the reporting period. Instead, it outlines the financial structure of a new licensing agreement:
- Upfront Payment: $7.35 million payable upon signing.
- Total Potential Milestone Payments: Approximately $32.55 million, contingent on FDA pre-submission meetings, approvals, and product launches in the U.S. and China.
- Royalty Structure:
- 5% one-time royalty on the first $50 million of gross profit in the U.S. and $20 million in China.
- Running royalties of 15% on annual gross profit up to $100 million, and 20% on amounts exceeding $100 million during the patent term.
- Post-patent royalties of 14% (up to $100 million) and 19% (exceeding $100 million).
- Payment Method: Cash or Circassia ordinary shares (at Circassia's option), with a 5% discount on share valuations. Cash payments for milestones are subject to a 4.7619% reduction.
Material Changes
The primary material change is the execution of the License, Development and Commercialization Agreement. AIT Therapeutics granted Circassia an exclusive, royalty-bearing license to distribute, market, and sell its nitric oxide generator and delivery system in the United States and China. This represents a strategic shift to partner for commercialization in these territories rather than self-distribution.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement secures immediate capital ($7.35 million) and potential future revenue streams tied to regulatory milestones and sales performance. The term extends until the last patent expires, with an automatic extension mechanism to maintain a constant three-year term thereafter.
Risks and Contingencies:
- Regulatory Risk: Significant milestone payments ($3.15 million, $12.6 million, $8.4 million) are contingent on FDA approvals and pre-submission meetings.
- Payment Uncertainty: Circassia has the option to pay in shares, which introduces valuation risk for AIT Therapeutics shareholders.
- License Reversion: If AIT Therapeutics is acquired by a competitor, enters bankruptcy, or materially breaches the agreement, Circassia gains a non-exclusive license to manufacture and sell the product.
- Termination: Either party may terminate for material default (uncured within 60 days) or bankruptcy events.
Investor Verification Checklist
- Verify the receipt of the $7.35 million upfront payment and its impact on the Company's cash position.
- Confirm the specific regulatory milestones required to trigger the $3.15 million and $12.6 million payments.
- Review the full text of the Agreement (filed in the subsequent 10-Q) for confidential terms and specific definitions of "gross profit."
- Assess the market value and liquidity of Circassia shares if the partner opts for stock payments.
- Monitor the Company's patent portfolio expiration dates to understand the duration of the royalty stream.